• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

关于 HIV-1 糖蛋白 gp120 与其核心受体 CCR5 相互作用和干扰的理论研究。

Theoretical studies on the interactions and interferences of HIV-1 glycoprotein gp120 and its coreceptor CCR5.

机构信息

School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China.

出版信息

J Chem Inf Model. 2011 Feb 28;51(2):359-69. doi: 10.1021/ci1003448. Epub 2011 Feb 2.

DOI:10.1021/ci1003448
PMID:21284403
Abstract

The interaction between the HIV gp120 protein and coreceptor CCR5 or CXCR4 of the host cell is critical in mediating the HIV entry process. A model for the CCR5-gp120 complex has been developed. In the model, the N-terminus of CCR5 binds to three discontinuous domains of gp120, including the fourth conserved (C4) region, β19/β20 connecting loop, and V3 loop. The second extra-cellular loop (ECL2) of CCR5 also interacts with the crown part of the gp120 V3 loop. The bindings of the three CCR5 antagonists, maraviroc, aplaviroc, and vicriviroc, to the trans-membrane domain of CCR5 have been modeled. The bindings are found to affect the conformation of the ECL2 domain, which in turn drives the N-terminus of CCR5 to an altered state. Aplaviroc is more hydrophilic than maraviroc and vicriviroc, and its binding is more interfered by solvent, resulting in a quite different effect to the structure of CCR5 compared with those of the other two molecules. The above results are in accord with experimental observations and provide a structural basis for further design of CCR5 antagonists.

摘要

HIV gp120 蛋白与宿主细胞的辅助受体 CCR5 或 CXCR4 的相互作用对于介导 HIV 进入过程至关重要。已经建立了 CCR5-gp120 复合物的模型。在该模型中,CCR5 的 N 端结合到 gp120 的三个不连续结构域,包括第四保守区(C4 区)、β19/β20 连接环和 V3 环。CCR5 的第二个细胞外环(ECL2)也与 gp120 V3 环的冠部相互作用。模拟了三种 CCR5 拮抗剂马拉维若、阿普拉维若和维立西罗的结合到 CCR5 的跨膜结构域。发现这些结合会影响 ECL2 结构域的构象,进而导致 CCR5 的 N 端进入改变的状态。阿普拉维若比马拉维若和维立西罗更亲水,其结合受到溶剂的干扰更大,因此与其他两种分子相比,对 CCR5 结构的影响完全不同。上述结果与实验观察结果一致,并为进一步设计 CCR5 拮抗剂提供了结构基础。

相似文献

1
Theoretical studies on the interactions and interferences of HIV-1 glycoprotein gp120 and its coreceptor CCR5.关于 HIV-1 糖蛋白 gp120 与其核心受体 CCR5 相互作用和干扰的理论研究。
J Chem Inf Model. 2011 Feb 28;51(2):359-69. doi: 10.1021/ci1003448. Epub 2011 Feb 2.
2
Electrostatic modeling of peptides derived from the V3-loop of HIV-1 gp120: implications of the interaction with chemokine receptor CCR5.源自HIV-1 gp120 V3环的肽段的静电建模:与趋化因子受体CCR5相互作用的意义
Int J Mol Med. 2007 Mar;19(3):343-51.
3
Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization.HIV-1 V3环C末端片段中的受限可变残基调节CCR5利用的分子结构。
J Mol Biol. 2005 Jul 22;350(4):699-712. doi: 10.1016/j.jmb.2005.05.024.
4
Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.生理和病毒趋化因子以及HIV-1包膜糖蛋白与CCR5结合的分子解剖学:RANTES、MIP-1α和vMIP-II结合的一级结构要求差异
J Mol Biol. 2001 Nov 9;313(5):1181-93. doi: 10.1006/jmbi.2001.5086.
5
Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage.HIV-1 V3环中调节共受体使用的新型遗传元件的鉴定与结构表征。
Antivir Ther. 2011;16(7):1035-45. doi: 10.3851/IMP1862.
6
Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5.临床对维立西洛耐药的 HIV-1 亚型 D gp120 中的适应性 V3 环突变,这些突变改变了与 CCR5 的 N 端和 ECL2 的相互作用。
Virology. 2010 Apr 25;400(1):145-55. doi: 10.1016/j.virol.2010.01.037. Epub 2010 Feb 21.
7
Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization.鉴定V3区中影响CCR5利用分子结构的ENV决定簇。
J Mol Biol. 2000 Sep 15;302(2):359-75. doi: 10.1006/jmbi.2000.4076.
8
Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.人类免疫缺陷病毒1型gp120的V1/V2和V3结构域与CXCR4受体相互作用的协同作用。
J Virol. 2001 Jun;75(12):5457-64. doi: 10.1128/JVI.75.12.5457-5464.2001.
9
Structural and functional characterization of the human CCR5 receptor in complex with HIV gp120 envelope glycoprotein and CD4 receptor by molecular modeling studies.通过分子模拟研究对与HIV gp120包膜糖蛋白和CD4受体复合的人CCR5受体进行结构和功能表征。
J Mol Model. 2003 Oct;9(5):329-36. doi: 10.1007/s00894-003-0154-9. Epub 2003 Aug 29.
10
Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.第二细胞外环的 C-C 趋化因子受体 5(CCR5)肽抑制多种 HIV-1 株。
J Biol Chem. 2012 Apr 27;287(18):15076-86. doi: 10.1074/jbc.M111.332361. Epub 2012 Mar 8.

引用本文的文献

1
Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies.HIV-1包膜蛋白在对CCR5拮抗剂西尼夫罗克和中和抗体耐药性方面的不相容特性
Antimicrob Agents Chemother. 2015 Nov 2;60(1):437-50. doi: 10.1128/AAC.02285-15. Print 2016 Jan.
2
Molecular recognition of CCR5 by an HIV-1 gp120 V3 loop.HIV-1 gp120 V3环对CCR5的分子识别。
PLoS One. 2014 Apr 24;9(4):e95767. doi: 10.1371/journal.pone.0095767. eCollection 2014.
3
Insights into the structure, correlated motions, and electrostatic properties of two HIV-1 gp120 V3 loops.
深入了解 HIV-1 gp120 V3 环的结构、相关运动和静电特性。
PLoS One. 2012;7(11):e49925. doi: 10.1371/journal.pone.0049925. Epub 2012 Nov 19.
4
HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120.HIV-1 对马拉维若的耐药性由包膜糖蛋白 gp120 中的 CD4 结合位点突变引起。
J Virol. 2013 Jan;87(2):923-34. doi: 10.1128/JVI.01863-12. Epub 2012 Nov 7.
5
Molecular dynamics simulation in virus research.病毒研究中的分子动力学模拟
Front Microbiol. 2012 Jul 19;3:258. doi: 10.3389/fmicb.2012.00258. eCollection 2012.
6
Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.第二细胞外环的 C-C 趋化因子受体 5(CCR5)肽抑制多种 HIV-1 株。
J Biol Chem. 2012 Apr 27;287(18):15076-86. doi: 10.1074/jbc.M111.332361. Epub 2012 Mar 8.